Regeneron Pharmaceuticals, Inc. REGN

788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Regeneron Pharmaceuticals, Inc. (REGN) Operating margin

Regeneron Pharmaceuticals, Inc.'s operating margin over the twelve months to 30 June 2026 was 24.7%, down 0.2 percentage points from fiscal 2025 (25.0%). Over the past ten years it has ranged from 25.0% (fiscal 2025) to 55.7% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Operating margin, annual

Annual

Period Operating margin Change (points)
FY2025 25.0% (3.15)
FY2024 28.1% (2.75)
FY2023 30.9% (8.08)
FY2022 38.9% (16.74)
FY2021 55.7% 13.58
FY2020 42.1% 8.39
FY2019 33.7% (15.55)
FY2018 49.3% 13.84
FY2017 35.4% 8.03
FY2016 27.4% (3.13)

Quarterly

Period Operating margin Change (points)
Jun 2026 30.2% 12.32
Mar 2026 17.8% (4.82)
Dec 2025 22.7% (4.70)
Sep 2025 27.4% (2.02)
42 more quarters

Against its own ten years

Low 25.0% High 55.7%
Ten-year median 33.7%
Current reading's percentile 9

Operating margin against peers

Company Operating margin
RPRX Royalty Pharma PLC compare 59.6%
VRTX Vertex Pharmaceuticals Incorporated compare 38.0%
ARGX argenex SE compare 30.1%
REGN Regeneron Pharmaceuticals, Inc. 24.7%
ALNY Alnylam Pharmaceuticals, Inc. compare 20.8%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 15.1%
RVMD Revolution Medicines, Inc. compare 0.00%
INSM Insmed, Inc. compare −73.9%
MRNA Moderna, Inc. compare −149.0%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.00%

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on REGN